Intellectual property issues of immune checkpoint inhibitors

被引：8

作者：

Storz, Ulrich ^{[1
,2
]}

机构：

[1] Michalski, Dusseldorf, Germany

[2] Huttermann Patent Attorneys, Dusseldorf, Germany

来源：

MABS | 2016年 / 8卷 / 01期

关键词：

antibody; CTLA4; Immune checkpoint inhibitors; Keytruda; Opdivo; patent; PD1; PD-L1; Yervoy; B7; FAMILY; CTLA-4; ANTIBODIES; CP-675,206; MELANOMA; THERAPY; MEMBER; B7-H1; PD-1;

D O I：

10.1080/19420862.2015.1107688

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

Immune checkpoint inhibitors are drugs that interfere with tumor escape responses. Some members of this class are already approved, and expected to be blockbusters in the future. Many companies have developed patent activities in this field. This article focuses on the patent landscape, and discusses key players and cases related to immune checkpoint inhibitors.

引用

页码：10 / 26

页数：17

共 50 条

[41] Management of endocrine immune-related adverse events of immune checkpoint inhibitors: an updated review
Stelmachowska-Banas, Maria
Czajka-Oraniec, Izabella
ENDOCRINE CONNECTIONS, 2020, 9 (10): : R207 - R228
[42] Immune Checkpoint Inhibitors in Gliomas
Tan, Aaron C.
Heimberger, Amy B.
Khasraw, Mustafa
CURRENT ONCOLOGY REPORTS, 2017, 19 (04)
[43] Endocrinopathies induced by immune-checkpoint inhibitors in advanced non-small cell lung cancer
Rossi, Emanuela
Sgambato, Assunta
De Chiara, Giovanni
Casaluce, Francesca
Losanno, Tania
Sacco, Paola Claudia
Santabarbara, Giuseppe
Gridelli, Cesare
EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2016, 9 (03) : 419 - 428
[44] Immunotherapy Based on Immune Checkpoint Molecules and Immune Checkpoint Inhibitors in Gastric Cancer-Narrative Review
Poniewierska-Baran, Agata
Sobolak, Karolina
Niedzwiedzka-Rystwej, Paulina
Plewa, Paulina
Pawlik, Andrzej
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (12)
[45] Endocrine Side Effects in Patients Treated with Immune Checkpoint Inhibitors: A Narrative Review
Profili, Nicia I.
Castelli, Roberto
Gidaro, Antonio
Merella, Alessandro
Manetti, Roberto
Palmieri, Giuseppe
Maioli, Margherita
Delitala, Alessandro P.
JOURNAL OF CLINICAL MEDICINE, 2023, 12 (15)
[46] A new biological triangle in cancer: intestinal microbiota, immune checkpoint inhibitors and antibiotics
Zhang, Jie
Dai, Zhujiang
Yan, Cheng
Zhang, Wenjie
Wang, Daorong
Tang, Dong
CLINICAL & TRANSLATIONAL ONCOLOGY, 2021, 23 (12) : 2415 - 2430
[47] Immune Checkpoint Inhibitors for Brain Metastases: A Primer for Neurosurgeons
Aquilanti, Elisa
Brastianos, Priscilla K.
NEUROSURGERY, 2020, 87 (03) : E281 - E288
[48] Immune Checkpoint Inhibitors and Cardiac Toxicity: An Emerging Issue
Varricchi, Gilda
Marone, Giancarlo
Mercurio, Valentina
Galdiero, Maria Rosaria
Bonaduce, Domenico
Tocchetti, Carlo G.
CURRENT MEDICINAL CHEMISTRY, 2018, 25 (11) : 1327 - 1339
[49] Analysis of combination therapy of immune checkpoint inhibitors in osteosarcoma
Peng, Lijun
Fang, Huapan
Yang, Xiao
Zeng, Xi
FRONTIERS IN CHEMISTRY, 2022, 10
[50] Immune checkpoint inhibitors and prostate cancer: a new frontier?
Modena, Alessandra
Ciccarese, Chiara
Iacovelli, Roberto
Brunelli, Matteo
Montironi, Rodolfo
Fiorentino, Michelangelo
Tortora, Giampaolo
Massari, Francesco
ONCOLOGY REVIEWS, 2016, 10 (01)

← 1 2 3 4 5 →